Ozempic Is Finally Turning the Tide Against Obesity, New Data Shows
New data indicates that GLP-1 medications, such as Ozempic and Wegovy, are showing effectiveness in reducing obesity rates across the U.S. The prescription rate for these drugs has increased significantly, coinciding with a slight decline in obesity prevalence. While the long-term impact remains uncertain, the findings suggest a potential shift in the obesity trend in America.
- ▪GLP-1 prescriptions among U.S. adults increased more than fourfold from 2021 to 2026.
- ▪The obesity rate in the dataset declined from 42% to 41% during the same period.
- ▪Only about 12% of Americans are currently taking a GLP-1 medication, which is below the obesity prevalence.
Opening excerpt (first ~120 words) tap to expand
New data seems to show that GLP-1 medications like semaglutide, the active ingredient in popular drugs Ozempic and Wegovy, are working on a population-wide level. Last late week, health analytics organization EPIC Research released two data trackers looking at the medical records of people across the country. The prescription rate of GLP-1 drugs in the U.S. has skyrocketed in recent years, the data shows, coinciding with a modest but sustained drop in the obesity rate. Though it’s still too early to tell, the long-term and widespread use of GLP-1s could finally start to help turn the tide against…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Gizmodo.
Discussion
0 commentsMore from Gizmodo
